Patrick Boland

RevMed with huge news for pancreatic cancer (daraxonrasib). The headline is hard to ignore 👀 • Median OS 13.2 vs 6.7 months • HR ~0.4 📉 • Activity across KRAS variants (not just G12C) • Manageable safety If that signal is real, this isn’t incremental. It changes how we think about KRAS. But—caveat applies ⚠️ This is a press release! PR as a rule is rosier than real data. Still… an OS HR like that gets your attention. Feels like we may be moving from mutation-specific inhibition → broader KRAS control. That’s the difference between niche utility and something that touches CRC, pancreas, lung… everything we see. Now we wait for the data behind the headline. @TheGutOncLab @OncoAlert @Onco_Nexus ir.revmed.com/news-releases/…

Neoantigen evolution and response to checkpoint inhibitor immunotherapy in colorectal cancer ⁦@NaturePortfolio⁩ nature.com/articles/s4146…

Congress rejected massive cuts to US science budgets for 2026, but much of the money still isn’t flowing to researchers. The culprit? The White House Office of Management and Budget (OMB) is quietly slow-walking the release of funds. 🧵👇 For @Nature: nature.com/articles/d4158…

Immune checkpoint inhibitor–induced #diabetes occurred in 0.52% of patients across 158 National Cancer Institute trials, with higher incidence for combination immunotherapy and lower rates when combined with #chemotherapy. ja.ma/4cxbt61

Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe. Read the full article. brnw.ch/21wZTLe

Colorectal cancer is now the leading cause of cancer deaths among people younger than 50 in the United States, according to a study. nbcnews.com/health/cancer/…

Colon cancer is now the leading cause of cancer deaths in Americans under age 50, and 75% are diagnosed at late stages, by @betswrites gift link wsj.com/health/healthc…

Immunological Dynamics in Rectal Cancer: SCRT vs LCRT @CCR_AACR ◾️Circulating lymphocytes: SCRT (less depletion) > LCRT ◾️Immune cells in TME: SCRT (higher density of CD8+ & FOXP3+) > LCRT, no diff. in FOXP3/CD8 ratio 👉SCRT is potentially preferred backbone in combination with ICIs doi.org/10.1158/1078-0… @OncoAlert @C_Roxburgh

Rx in R/R metastatic colorectal cancer, outside trials, if there is no 🎯mutations, are limited! Dose optimization is important! 1. Biweekly dosing for TAS102 by @CathyEngMD @ChrisMCann et al 2. ReDOS Regorafenib dosing by @GIcancerDoc et al 3. Fruquintinib 5mg: 21 on/7 off

Congratulations to Dr. Iyer on becoming the new CMO of the @NCCN! Having learned so much under her guidance, I’m beyond grateful for her mentorship, kindness, and example of what true leadership looks like. A real #BossLady changing the future of cancer care. @WomenInOncology

In 2024, Elsevier publishers, parent company of @sciencedirect reported profits of over 3 Billion pounds and @SpringerNature reported over 1.8 billion pounds of profit. All off the work we do for them for free. Hey publishers, pay for reviews.

Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic | JCO Precision Oncology ⁦@OncoAlert⁩ ⁦@ASCO⁩ ascopubs.org/doi/10.1200/PO…

The MIAmS assay holds promise in the present landscape, but it is not alone. @PMBolandMD and Shridar Ganesan MD, PhD of @RutgersCancer comment on the recent study by Quentin Dominique Thomas MD et al: acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert #ArtificialIntelligence

cT3/T4 per CT identifies patients with dMMR colon cancer with substantial risk of recurrence despite FOLFOX: cT3N0: 84% 3-year DFS cT4N0: 70% 3-year DFS Of course, NICHE2 : 100% 3-year DFS for cT3/4 For patients with dMMR colon cancer cT3/T4 by CT: we should discuss risks and benefits of neoadjuvant IO vs surgery and adjuvant therapy. We should recommend neoadjuvant IO for cT4N0.

Many options, no head-to-head comparison, challenging scenario: join @PMBolandMD and I in this @OncLive Ask the Expert meeting - Advanced Colorectal Cancer: Optimizing Later-Line Treatment Strategies and Emerging Evidence in Metastatic Disease Management @CCAlliance @FightCRC @MoffittNews Register here: globalmeet.webcasts.com/starthere.jsp?…

And the plot thickens for short course RT in rectal cancer! 72% cCR & 57% 2-year TME free survival via 4 cycles FOLFOX/CAPOX --> 25-30Gy/5 fraction RT (short course with optional boost). Congrats @adapthyun & looking forward to study details. #ASTRO25

From the @myESMO "cancer of unknown primary" management guideline; Recommended IHC markers for differential diagnosis👇 annalsofoncology.org/article/S0923-…

Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer @NEJM doi.org/10.1056/NEJMdo… 👉Low-dose aspirin resulted in a significantly lower risk of recurrence w/ hotspot mutations 👉similar benefit w/ other alterations in PI3K pathway 🧐I would take it... @myESMO

Vitamin B12 for prophylaxis of capecitabine-associated hand–foot syndrome 💥Oral methylcobalamin reduced capecitabine-related HFS in HER2-negative early BC, with no added safety concerns 💬A simple prophylaxis option to support treatment adherence bmj.com/content/390/bm…

Hmm...